Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.

Abstract

BACKGROUND Prospective data on chemotherapy for (frail) elderly patients with advanced colorectal cancer (aCRC) are scant. UFT/leucovorin might be as effective as and less toxic than capecitabine. We firstly randomized both agents in patients >65 years with aCRC not amenable to receive combination chemotherapy. PATIENTS AND METHODS Patients were… (More)
DOI: 10.1016/j.jgo.2015.05.004

Topics

Cite this paper

@article{Kroep2015RandomisedSO, title={Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.}, author={Judith R. Kroep and Erik D van Werkhoven and Marco B. Polee and Cees J. van Groeningen and Aart Beeker and Frans L. G. Erdkamp and Nir I Weijl and Aart van Bochove and Zoran Erjavec and Ellen H W Kapiteijn and Anne M. Stiggelbout and Hans J W R Nortier and Hans Gelderblom}, journal={Journal of geriatric oncology}, year={2015}, volume={6 4}, pages={307-15} }